DermTech, Inc.

DMTK

US24984K1051

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 02:44:05 2024-05-16 pm EDT			5-day change	1st Jan Change
0.57 ^USD	-0.02%		-8.82%	-67.70%

May. 14	Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M	MT
Apr. 22	North American Morning Briefing : Stock Futures -2-	DJ

DermTech, Inc. Provides Assay Revenue Guidance for the First Quarter of 2021

March 04, 2021 at 04:01 pm EST

DermTech, Inc. provided assay revenue guidance for the first quarter of 2021. Management estimates that first quarter 2021 assay revenue will be between $1.6 and $1.9 million.

Latest news about DermTech, Inc.

Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M	May. 14	MT
North American Morning Briefing : Stock Futures -2-	Apr. 22	DJ
Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63	Apr. 19	MT
BTIG Downgrades DermTech to Neutral From Buy	Apr. 19	MT
DermTech Explores Strategic Alternatives to Boost Shareholder Value, Lays Off 100 Employees in Restructuring Plan	Apr. 18	MT
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	Apr. 17	CI
BTIG Adjusts DermTech's Price Target to $2 From $4, Maintains Buy Rating	Mar. 07	MT
Stephens Trims Price Target on DermTech to $1.50 From $2.50, Keeps Equalweight Rating	Mar. 05	MT
Transcript : DermTech, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
DermTech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
DermTech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (DMTK) DERMTECH Reports Q4 Revenue $3.9M, vs. Street Est of $4.03M	Feb. 29	MT
Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer	Jan. 31	CI
DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test Across All Skin Types	Jan. 18	CI
DermTech, Inc. Simplifies the DermTech Melanoma Test by Discontinuing the Optional TERT Add-On Assay	Jan. 16	CI
Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test	Jan. 08	CI
Transcript : DermTech, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
DermTech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (DMTK) DERMTECH Posts Q3 Revenue $3.9M, vs. Street Est of $3.9M	Nov. 02	MT
DermTech Signs Contract With Highmark For Enhanced Access to DermTech Melanoma Test	23-09-19	MT
DermTech Inc Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test	23-09-19	CI
Dermtech Appoints Mark Aguillard as Chief Commercial Officer	23-09-11	CI
BTIG Adjusts Price Target on DermTech to $5 From $6, Maintains Buy Rating	23-08-07	MT
Transcript : DermTech, Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
DermTech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI

DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for DermTech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5701 USD

Average target price

2.043 USD

Spread / Average Target

+258.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
DERMTECH, INC.	-67.70%	19.74M
BIOMÉRIEUX	-4.57%	12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.35%	8.1B
DIASORIN S.P.A.	+8.91%	5.87B
LANTHEUS HOLDINGS, INC.	+30.06%	5.52B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.42%	4.29B
10X GENOMICS, INC.	-54.18%	3.16B
ANDON HEALTH CO., LTD.	+14.44%	2.72B
VITROLIFE AB	-2.21%	2.37B
MYRIAD GENETICS, INC.	+28.37%	2.23B

Diagnostic & Testing Substances

DermTech, Inc.

Equities

DMTK

US24984K1051

Medical Equipment, Supplies & Distribution

DermTech, Inc. Provides Assay Revenue Guidance for the First Quarter of 2021

Latest news about DermTech, Inc.

Chart DermTech, Inc.

Company Profile

Income Statement Evolution

Ratings for DermTech, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances